Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.52, p.185-192, 2005 |
||
Title: Inhibitors of proteases as anticancer drugs | ||
Author: A., JEDINAK ; T., MALIAR ; | ||
Abstract: Proteolytic processes are necessary for normal physiological
functions in the body. Failure in the biological control
mechanisms of proteolytic activities may cause various diseases,
for example, it may enable tumor invasion and metastasis.
In the metastatic process, proteolytic enzymes play an important
role in mediating passage of the malignant cell through the
cell membrane. Tumor cell migration and invasion into the
surrounding extracellular matrix is facilitated by a variety of
cell
surface-associated proteolytic enzymes: matrix metalloproteinases
(MMPs), cysteine proteases including cathepsins B and
L, aspartic protease cathepsin D, and serine proteases including
plasmin and urokinase plasminogen activator (uPA). Many
of the natural and synthetic inhibitors of the proteases prevent
the dissemination of cancer cells and have also inhibitory effect
on tumor growth. Thus inhibition of protease activity by low
molecular weight inhibitors represents a promising strategy
for anticancer and antimetastatic therapy. The review surveys low
molecular inhibitors of MMPs, uPA and lysosomal
proteases.
|
||
Keywords: protease inhibitors, tumor metastasis, lysosomal proteases, anticancer drugs | ||
Year: 2005, Volume: 52, Issue: | Page From: 185, Page To: 192 | |
|
download file |
|